Anocca

We’re set to join industry leaders in Stockholm at BIO-Europe 2024 from November 4-6, where we’ll be discussing the transformative potential of TCR-T cell therapies as event sponsors and as part of the Swedish Pavillion. Meet us there: 🤝 https://lnkd.in/dRGyPtmn Reagan Jarvis joins a high-profile panel together with Romain Bonnot, Pharm.D (ZS), Celine Carlet (Galapagos), Michael May (CCRM), Bernd Muehlenweg (Evotec) and Dan Kemp from our strategic partners Shinobi Therapeutics. They will explore how cell and gene therapy can reshape healthcare, focusing on advances in therapeutic applications, disease treatment, and prevention. Mark Farmery, Jacob Michlewicz and Zach Chia will also be in attendance, ready to discuss the progress of our KRAS program and our upcoming transition to a clinical stage company, along with the development of our pipeline and opportunities for investment, collaboration and partnership. 🤝 Schedule a meeting with us: https://lnkd.in/dRGyPtmn 🔗 #BIOEurope2024: https://lnkd.in/dnuNZ2D #Biotech #Pharma #Innovation #CellTherapy #CancerResearch #TCR #JoinSwedishLifeScience #InnovationforLife Informa Connect Life Sciences

Join us at the European Society of Gene and Cell Therapy annual congress in Rome from October 22-25, where our CTO Luke Pase will present a poster on Anocca’s clinical TCR candidate library development. 📅 October 24 | 14:00–15:30 | Poster Session 3 | P0771 Establishing a clinical TCR candidate library through systematic and scalable cell-based platform Learn how our platform discovers peptide-HLA (pHLA) targets and therapeutic TCRs at a scale to enable TCR-T library deployment for personalised therapy. Our lead TCR-T product, targeting shared KRAS tumour antigens, is progressing to clinical trials, marking the first step in a broader program aimed at hard-to-treat solid tumours. 🔗 Join us at ESGCT Congress 2024: https://lnkd.in/efye-f8c #Biotech #Pharma #CellTherapy #Oncology #TCRT #ESGCT2024

Mark Farmery led a workshop at Nordic Life Science Days 2024 in Malmo exploring innovation, collaboration, and the future of cell & gene therapy in the Nordics. Joined by  Elsa Abranches (AstraZeneca), Janet Hoogstraate (NorthX Biologics), and Fredrik Wessberg (CCRM Nordic), the session sparked dynamic discussions on driving CGT forward. Discover how: 🌐The Nordic region is poised to lead innovation in CGT, backed by strong healthcare infrastructure and cutting edge research 🤝Collaboration is critical to reduce production costs and drive productivity in CGT 💡 The Nordic ecosystem plays a key role in attracting and nurturing top talent ⚙️ Standardisation is essential for efficient scaling and production of advanced therapies 🔗Read the full feature to dive into the key takeaways and learn how Anocca is shaping the future of cell & gene therapy: https://lnkd.in/dMH5RA9t #Biotech #Pharma #CellAndGeneTherapy #TCR #Nordics #NLSDays2024 Scius Communications

We’re excited to be joining the LSX Nordic Congress in Copenhagen where co-founder and CEO Reagan Jarvis will be participating as an expert speaker. 📅 October 9 | 11.00-11:50 | Nordic Biotech Brilliance: Unleashing the Talent Magnet for Sustained and Retained Innovation This session will explore how the Nordic region can attract and retain top-tier talent to sustain innovation in biotech and pharma. We are advancing to the clinic with our multi-asset mutant KRAS program that has been developed by our proprietary platform technologies and in-house manufacturing capabilities. To learn more, schedule a 1:1 meeting with Reagan: https://lnkd.in/e_bDpN4W 🔗Register for #LSXNordic2024: https://lnkd.in/eCkHc4Rq #Pharma #Biotech #CellTherapy #TCRT LSX - partnering for Life Science eXecutives Mario Alzamora (Nucleate Denmark, Georgina Askeland, PhD (Hadean Ventures), Stine Kruse (DTU Skylab)

Meet with our CDO Mark Farmery at the Alliance for Regenerative Medicine’s 2024 Cell and Gene Meeting on the Mesa in Phoenix from October 7-9, and join our company presentation. 👉 https://lnkd.in/edKBRYf 📅 8 October | 11:30-11:45 | FLW Ballroom G Mark will share an update on recent progress across the company, including our multi-asset TCR-T program targeting KRAS driver mutations, which is advancing into clinical development. 🔗Event info: https://lnkd.in/eiUpMy4 🤝Schedule a meeting with Mark: https://lnkd.in/edKBRYf #biotech #pharma #celltherapy #innovation #TCR

Our CFO, Jacob Michlewicz was delighted to share our perspectives on #biotech funding and #finance at the recently concluded Nordic Life Science Days. Read about it below. #investmentstrategy #lifescience

Our CFO Jacob Michlewicz and CDO Mark Farmery had a very fruitful Nordic Life Science Days last week with great discussions throughout the event. We would like to say thank you to our fellow panellists and the organisers, SwedenBIO!   Thank you to Inka Mero(Voima Ventures), Laurenz Govaerts (EQT Life Sciences), Jonathan P. Gertler, MD (Back Bay Life Science Advisors), and Diana Röttger, PhD (APEX Ventures), for the enlightening panel discussion with Jacob on attracting more international investors to the Nordics   Thank you also to Elsa Abranches (AstraZeneca), Janet Hoogstraate (NorthX Biologics), and Fredrik Wessberg  (CCRM Nordic), for a fantastic workshop together with Mark to explore the Nordic opportunity in CGT

Thank you Brad Loncar and BiotechTV for meeting with Reagan Jarvis, our CEO, at Anocca HQ to discuss how we are tackling key cancer drivers such as KRAS and p53 with our precise, scalable, and differentiated approach to mapping disease targets and developing therapeutic TCRs 👇

Our CSO Hugh Salter along with our CMO Zahid Bashir, MBBS, MSc Oncology, Director of Clinical Development Sheila Forsman and Clinial Science Lead Rehab Alnabhan presented preclinical data at #ESMO24 on our TCR-T cell therapies targeting mutated KRAS. The poster introduced our novel platform, which systematically recreates human T-cell biology to map targets and generate therapeutic TCR libraries to enable in-house manufacturing of a deep pipeline of products that addresses a broad range of hard-to-treat solid tumour cancers. The data showcased the development of our lead TCR-T product targeting KRAS-G12V, a critical driver in cancers like pancreatic, lung, and colon, that is advancing toward clinical trials. We were pleased to have been shortlisted for best poster in the section (investigational immunotherapy)!  🔗 See the poster: https://lnkd.in/exUBSvQU #biotech #pharma #celltherapy #innovation #TCR ESMO - European Society for Medical Oncology

Join us at the RAS-Targeted Drug Development Summit in Boston from September 24-26 where our co-founder and CEO Reagan Jarvis will present expert insights into our precision approach to advancing TCR-T therapies for RAS mutant cancers. 📅 September 25 | 12.15-12:45  |  RAS Mutant Targeting TCR-T Development & Manufacturing Discover how we’re leveraging cutting-edge target mapping and gene editing technologies to enhance both the development and scalability of TCR-T therapies aimed at KRAS mutations. Our innovative approach is paving the way for more effective treatments for some of the most challenging cancers. We’re also advancing towards our first clinical program, targeting multiple KRAS mutation forms across diverse patient segments. 🔗Register for RAS-Targeted Drug Development Summit: https://lnkd.in/d-29jaH 🔗See the full agenda here: https://lnkd.in/ehYkXpJ7 #Biotech #Pharma #CellTherapy #Oncology #TCR Hanson Wade Group